



GROUP OVERVIEW

- Aspen Pharmacare Holdings Limited ("Aspen" or "the Group") is a global supplier of branded and generic pharmaceutical products in approximately 150 countries and of consumer and nutritional products in selected territories. The Group has a proud heritage dating back to more than 160 years.
- Aspen products are renowned for their quality, efficacy and affordability.
- Aspen operates in South Africa, Asia Pacific (including Australia, Philippines and Hong Kong), Sub-Saharan Africa (including Kenya, Uganda, Tanzania) and Internationally (including Mexico, Venezuela, Brazil, Mauritius, United Arab Emirates, Ireland and Germany).
- Aspen is the leading supplier of generic medicines to both the private and public sectors in South Africa. Close to one in every four scripts dispensed in South African pharmacies is for an Aspen product.
- Aspen is also the generics market leader in Australia, in value (net sales) and by volume for Aspen distributed products.
- Aspen is a leading generics manufacturer in the southern hemisphere and is Africa's largest pharmaceutical manufacturer.
- Aspen has 22 manufacturing facilities at 16 sites on six continents. Four of the sites are located in South Africa, two in each of Australia and the Netherlands, and one each in Kenya, Tanzania, Brazil, Mexico, Germany and the United States. Global manufacturing capability is at nearly 20 billion tablets.
- Aspen has an outstanding generic pipeline. These products are developed under the direction of highly skilled scientists employed by Aspen and in collaboration with other global pharmaceutical companies and research facilities.

GROUP REVENUE AND EBITA* MARGIN



GROUP REVENUE BY REGION – year ended 30 June 2013



Region	Product offering	Number of products launched in 2013	IMS value of product pipeline in next five years (US\$'million) as at 30 June 2013
South Africa	Branded, generics, over-the-counter ("OTC"), consumer and nutritionals	22	634
Asia Pacific	Branded, generics, OTC, consumer and nutritionals	9	4 536
Sub-Saharan Africa	Branded, generics, OTC, consumer and nutritionals	35	3
International	Branded, generics, OTC, consumer and nutritionals	4	3 729
Total		70	8 902

SHARE AND MARKET DATA

Primary listing:

Johannesburg Stock Exchange ("JSE"), South Africa

JSE share/ticker symbol:

APN

JSE sector:

Pharmaceuticals and Biotechnology

ISIN:

ZAE 000066692

Market capitalisation:

R114,8 billion (US\$11,3 billion)*

Number of shares outstanding:

~456,2 million*

Institutional ownership:

~50%

Reporting currency:

South African Rand ("R/ZAR")

Year end:

June

*As at 21 November 2013.

BOARD OF DIRECTORS

Executive directors

Group Chief Executive: Stephen Saad

Deputy Group Chief Executive: Gus Attridge

Non-executive directors

Chairman: Dr Judy Dlamini

Directors: Roy Andersen, Rafique Bagus,

John Buchanan, Kuseni Dlamini,

Abbas Hussain, Chris Mortimer

and Sindi Zilwa

COMPANY DATA:


Number of employees globally: ~8 200

Reporting currency: South African Rand ("R/ZAR")

FIVE-YEAR SHARE PERFORMANCE

Aspen is listed on the JSE and is included in the JSE Top 40 Index.

Performance vs indices: JSE All Share ("JALSH"), MSCI Emerging Markets ("MXEF") and S&P Global Healthcare Sector ("IXJIV")



52-week range: 15 411 cents – 27 978 cents


Share price as at 21 November 2013: 25 153 cents

FINANCIAL RATIOS

Key performance indicators	2013	2012	2011
Revenue growth from continuing operations (%)	26,6	23,2	28,7
Gross margin (%)	47,8	47,7	45,3
EBITA* margin (%)	27,0	27,0	26,4
Return on ordinary shareholders' equity (%)	17,7	17,3	18,4
Return on total assets (%)	16,4	16,5	17,3
Gearing ratio (%)	32,7	28,9	33,7
Net interest cover	9,4	8,7	8,5
Working capital as % of revenue (%)	27,0	27,2	22,5

* EBITA represents operating profit from continuing operations before amortisation adjusted for specific non-trading items.

CAPEX AND DEPRECIATION (R'million)



MILESTONES

- 2013** Aspen Global, a wholly owned subsidiary of Aspen Holdings, acquired the Arixtra and Fraxiparine/Fraxodi brands and business worldwide from GSK (except in China, Pakistan and India) from January 2014 and Aspen Holdings acquired specialised sterile production site in France from GSK as from May 2014 for £600 million collectively.
Aspen acquired an active pharmaceutical ingredient manufacturing business located in the Netherlands with a satellite facility and sales office in the US effective 1 October 2013 and reached an agreement on an option to acquire a portfolio of 11 branded finished dose form molecules from MSD, covering a diverse range of therapies effective 31 December 2013 for approximately US\$1 billion.
Aspen acquired the infant nutritional business for the Australian and certain southern African territories from Nestlé for US\$215 million in May 2013. An additional agreement was reached with Nestlé for the acquisition of the infant nutritional business in Latin America on 28 October 2013.
- 2012** Aspen Global acquired a portfolio of 25 established pharmaceutical brands ("Classic Brands") from GSK to be distributed in Australia for R2,2 billion.
Aspen acquired a portfolio of established GSK OTC products in selected territories for R2,1 billion.
Aspen Philippines began trading in March 2012.
- 2011** Aspen acquired the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited for R5,9 billion.
- 2010** Aspen took full control of the Latin American businesses.
- 2009** Aspen concluded a series of strategic transactions with GSK worth R4,6 billion for (1) the acquisition of the rights to distribute GSK's pharmaceutical products in South Africa, (2) the formation of The GSK Aspen Healthcare for Africa Collaboration in Sub-Saharan Africa ("the Collaboration") to market and sell pharmaceuticals in SSA, (3) the acquisition of eight specialist branded products for worldwide distribution and (4) the acquisition of a manufacturing site in Bad Oldesloe, Germany.
- 2008** Aspen Global acquired the intellectual property rights to four GSK branded products for R2,7 billion to distribute these global brands, namely Eltroxin, Imuran, Lanoxin and Zyloric, to more than 100 countries.
Aspen acquired 60% of the share capital of Shelys with businesses in Kenya, Tanzania and Uganda.
Aspen entered the Latin American market through an investment with Strides in businesses established in Brazil, Mexico and Venezuela.
- 2007** Prestige Brands entered into an agreement with Aspen for the supply of eye drops from Aspen's Sterile facility in Port Elizabeth to the United States market.
- 2006** Aspen secured distribution rights for a number of antiretrovirals ("ARVs") from MSD, BMS, Roche and Tibotec, thereby extending its portfolio as the biggest supplier of ARVs in Africa.
- 2005** Aspen's Unit 1 facility in Port Elizabeth became the world's first manufacturing site to receive tentative United States Food and Drug Administration approval for the production of certain generic ARVs.
- 2004** Aspen's multi-million Rand Unit 1 facility based in Port Elizabeth became operational.
- 2003** Aspen entered into agreement with GSK for the marketing and distribution of 40 branded products into the South African private sector.
- 2001** Aspen Australia commenced trade as a start-up.
- 1999** Aspen acquired South African Druggists' business for R2,4 billion.
- 1998** Aspen was listed on the JSE Limited.
- 1997** Aspen Healthcare (Pty) Limited began trading.
- 1850** Commencement of the business in Port Elizabeth, South Africa, which later became Lennon Limited, the originator company to the Group today.

CONTACTS

Company Secretary and Group Governance Officer: Riaan Verster
rverster@aspenpharma.com

Investor Relations: Nondybo Mqulwana
nmqulwana@aspenpharma.com

Media Enquiries: Shauneen Beukes
shauneen.beukes@me.com

